THE PHARMACEUTICAL MANAGERS' INSTITUTE
LEARN|CONNECT|GROW

Market Round-up

V22 – 19th October 2018

General Market News:

- **Ger Brennan** and ***MSD Ireland*** have announced they are to create 170 new jobs in Carlow.
  LINK

- **HSE** secures lifting of contract suspension for the supply of ***GSK***'s **Infanrix Hex** of 6 in 1 vaccines.
  LINK

- ***GSK*** has appointed **Publicis Media** as its global media buying and planning agency. The account is estimated to be worth $1.7bn.
  LINK

- ***Shire*** announces UCD master's scholarship in biopharmaceutical engineering
  LINK

- The **MMP** is currently undertaking a period of consultation in relation to their Roadmap for the prescribing of best-value biological (BVB) medicines (including biosimilars). Details of this consultation, including the draft document, can be found in the consultation section of the MMP website.
  LINK

- ***Roche's*** **Kadcyla** shows promise in early breast cancer during Phase III trials.
  LINK

- ***AstraZeneca*** and ***MSD's*** PARP inhibitor **Lynparza** has been granted orphan drug designation in the US for the treatment of pancreatic cancer.
  LINK

- ***HSE*** told to reinstate consultants' pay scales
  LINK

- ***Pfizer*** is cutting about 2% of its workforce by early 2019
  LINK

- **NICE** rejects ***Eli Lilly's*** breast cancer drug **Verzenios**
  LINK

NCPE Drug Updates

- A full HTA is recommended to assess the clinical effectiveness of ***Novartis's*** **Kymriah**
  LINK

- A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ***Gilead's*** **Yescarta**
  LINK

- A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ***AbbVie's*** **Venclyxto**
  LINK

Biologics / Biosimilars:

- "The ***HSE*** may miss out on €37m savings as costly drug **Humira** comes off patent as the policy of switching to biosimilar drugs was never adopted" *Irish Times article*
  LINK

- ***AbbVie*** settles **Humira** biosimilar patent disputes with ***Novartis***
  LINK

- ***Amgen*** has begun launching **Amgevita**, the first biosimilar of ***AbbVie's*** anti-inflammatory blockbuster **Humira** to win approval in Europe, across the region.
  LINK

- ***Samsung Bioepis*** has announced the European launch of **Humira** biosimilar **Imraldi**, as NHS chiefs tell Trusts to ensure they are ready to realise the potential savings from using cheaper versions of the world's biggest selling drug.
  LINK

- ***MDS*** drops **Lantus** biosimilar, blames pricing and production cost concerns
  LINK

Drug Approvals:

- ***Pfizer*** has received approval from the FDA for **Talzenna** (talazoparib), its PARP inhibitor for a genetically defined line of breast cancer.
  LINK

Drug Approval Submissions:

- US and European regulators have accepted filings for ***Novartis's*** **siponimod** for secondary progressive multiple sclerosis (SPMS).
  LINK

- The FDA's Gastrointestinal Drugs Advisory Committee convened on Thursday, October 18, to review and discuss a marketing application from ***Shire*** for their constipation medicine **prucalopride**
  LINK

- ***ViiV Healthcare*** has submitted a New Drug Application to the FDA for their two-drug, single pill HIV treatment
  LINK

Brexit:

- **Batch Testing** And Brexit: 4 Things You Need To Know
  LINK

- The UK Pharmaceutical Industry Braces for Brexit
  LINK

- Brexit: 'No optimism' for summit breakthrough, says Donald Tusk
  LINK

Further Reading:

- Tufts study uncovers the economic advantage of single-source drug development and manufacturing
  LINK

- Fighting The Opioid Epidemic: How Grünenthal's Abuse-Deterrent Technology Contributes
  LINK
